Milo R, Kahana E (março de 2010). «Multiple sclerosis: geoepidemiology, genetics and the environment». Autoimmunity Reviews. 9 (5): A387-94. PMID19932200. doi:10.1016/j.autrev.2009.11.010
Nakahara J, Maeda M, Aiso S, Suzuki N (fevereiro de 2012). «Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy». Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. PMID22189514. doi:10.1007/s12016-011-8287-6
Rosati G (abril de 2001). «The prevalence of multiple sclerosis in the world: an updata». Neurol. Sci. 22 (2): 117–39. PMID11603614. doi:10.1007/s100720170011
Ascherio A, Munger KL (abril de 2007). «Environmental risk factors for multiple sclerosis. Part I: the role of infection». Ann. Neurol. 61 (4): 288–99. PMID17444504. doi:10.1002/ana.21117
Petzold A, Fraser CL, Abegg M; et al. (2022). «Diagnosis and classification of optic neuritis». The Lancet Neurology. 21 (12): 1120–1134. PMID36179757. doi:10.1016/S1474-4422(22)00200-9 !CS1 manut: Uso explícito de et al. (link) !CS1 manut: Nomes múltiplos: lista de autores (link)
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). «Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis». Neuroepidemiology. 27 (1): 28–32. PMID16804331. doi:10.1159/000094233 !CS1 manut: Nomes múltiplos: lista de autores (link)
Heesen C, Mohr DC, Huitinga I; et al. (março de 2007). «Stress regulation in multiple sclerosis: current numeros and concepts». Mult. Scler. 13 (2): 143–8. PMID17439878. doi:10.1177/1352458506070772 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dyment DA, Ebers GC, Sadovnick AD (fevereiro de 2004). «Genetics of multiple sclerosis». Lancet Neurol. 3 (92): 104–10. PMID14747002. doi:10.1016/S1474-4422(03)00663-X !CS1 manut: Nomes múltiplos: lista de autores (link)
Ascherio A, Munger KL (junho de 2007). «Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors». Ann. Neurol. 61 (6): 504–13. PMID17492755. doi:10.1002/ana.21141
Ascherio A, Munger KL, Simon KC (junho de 2010). «Vitamin D and multiple sclerosis». Lancet Neurol. 9 (6): 599–612. PMID20494325. doi:10.1016/S1474-4422(10)70086-7 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R (1998). «Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada». Int J Epidemiol. 27 (5): 845–52. PMID9839742. doi:10.1093/ije/27.5.845 !CS1 manut: Nomes múltiplos: lista de autores (link)
Pittock SJ, Lucchinetti CF (março de 2007). «The pathology of MS: new insights and potential clinical applications». Neurologist. 13 (2): 45–56. PMID17351524. doi:10.1097/01.nrl.0000253065.31662.37
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (novembro de 2001). «T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis». Glia. 36 (2): 220–34. PMID11596130. doi:10.1002/glia.1111 !CS1 manut: Nomes múltiplos: lista de autores (link)
Poser CM, Brinar VV (junho de 2004). «Diagnostic criteria for multiple sclerosis: an historical review». Clin Neurol Neurosurg. 106 (3): 147–58. PMID15177763. doi:10.1016/j.clineuro.2004.02.004
McDonald WI, Compston A, Edan G; et al. (julho de 2001). «Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis». Ann. Neurol. 50 (1): 121–7. PMID11456302. doi:10.1002/ana.1032 !CS1 manut: Nomes múltiplos: lista de autores (link)
Polman CH, Reingold SC, Edan G; et al. (dezembro de 2005). «Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"». Ann. Neurol. 58 (6): 840–6. PMID16283615. doi:10.1002/ana.20703 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rashid W, Miller DH (fevereiro de 2008). «Recent advances in neuroimaging of multiple sclerosis». Semin Neurol. 28 (1): 46–55. PMID18256986. doi:10.1055/s-2007-1019127
Link H, Huang YM (novembro de 2006). «Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an updata on methodology and clinical usefulness». J. Neuroimmunol. 180 (1–2): 17–28. PMID16945427. doi:10.1016/j.jneuroim.2006.07.006
Pittock SJ, Rodriguez M (2008). «Benign multiple sclerosis: a distinct clinical entity with therapeutic implications». Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology. 318: 1–17. ISBN978-3-540-73676-9. PMID18219812. doi:10.1007/978-3-540-73677-6_1
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (maio de 2005). «Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis». Lancet Neurol. 4 (5): 281–8. PMID15847841. doi:10.1016/S1474-4422(05)70071-5 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (abril de 2006). «Secondary progressive multiple sclerosis: current knowledge and future challenges». Lancet Neurol. 5 (4): 343–54. PMID16545751. doi:10.1016/S1474-4422(06)70410-0 !CS1 manut: Nomes múltiplos: lista de autores (link)
Stadelmann C, Brück W (novembro de 2004). «Lessons from the neuropathology of atypical forms of multiple sclerosis». Neurol. Sci. 25 (Suppl 4): S319–22. PMID15727225. doi:10.1007/s10072-004-0333-1
Burton JM, O'Connor PW, Hohol M, Beyene J (2009). Burton, Jodie M, ed. «Oral versus intravenous steroids for treatment of relapses in multiple sclerosis». Cochrane Database Syst Rev (3): CD006921. PMID19588409. doi:10.1002/14651858.CD006921.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Comi G (outubro de 2009). «Treatment of multiple sclerosis: role of natalizumab». Neurol. Sci. 30. Suppl 2 (S2): S155–8. PMID19882365. doi:10.1007/s10072-009-0147-2
Johnson KP (2007). «Control of multiple sclerosis relapses with immunomodulating agents». J. Neurol. Sci. 256 (Suppl 1): S23–8. PMID17350652. doi:10.1016/j.jns.2007.01.060
Martinelli Boneschi F, Rovaris M, Capra R, Comi G (2005). Martinelli Boneschi, Filippo, ed. «Mitoxantrone for multiple sclerosis». Cochrane database of systematic reviews (Online) (4): CD002127. PMID16235298. doi:10.1002/14651858.CD002127.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Munari L, Lovati R, Boiko A (2004). Munari, Luca M., ed. «Therapy with glatiramer acetate for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD004678. PMID14974077. doi:10.1002/14651858.CD004678 !CS1 manut: Nomes múltiplos: lista de autores (link)
Tremlett H, Oger J (novembro de 2004). «Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis». J. Neurol. 251 (11): 1297–303. PMID15592724. doi:10.1007/s00415-004-0619-5
Khan F, Turner-Stokes L, Ng L, Kilpatrick T (2007). Khan, Fary, ed. «Multidisciplinary rehabilitation for adults with multiple sclerosis». Cochrane Database Syst Rev (2): CD006036. PMID17443610. doi:10.1002/14651858.CD006036.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Smith, Cath; Leigh Hale; Kärin Olson; Anthony Schneiders (2009). «How does exercise influence fatigue in people with multiple sclerosis?». Disability and Rehabilitation. 31 (9): 685–692. PMID18841515. doi:10.1080/09638280802273473 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G (2005). Kwakkel, Gert, ed. «Exercise therapy for multiple sclerosis». Cochrane Database of Systematic Reviews. CD003980 (1): CD003980. PMID15674920. doi:10.1002/14651858.CD003980.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dalgas U, Stenager E, Jakobsen J; et al. (2009). «Resistance training improves muscle strength and functional capacity in multiple sclerosis». Neurology. 73 (18): 1478–1484. PMID19884575. doi:10.1212/WNL.0b013e3181bf98b4 !CS1 manut: Nomes múltiplos: lista de autores (link)
Olsen SA (2009). «A review of complementary and alternative medicine (CAM) by people with multiple sclerosis». Occup Ther Int. 16 (1): 57–70. PMID19222053. doi:10.1002/oti.266
Farinotti M, Simi S, Di Pietrantonj C; et al. (2007). Farinotti, Mariangela, ed. «Dietary interventions for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD004192. PMID17253500. doi:10.1002/14651858.CD004192.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (2006). «Cannabis use in patients with multiple sclerosis». Mult. Scler. 12 (5): 646–51. PMID17086912. doi:10.1177/1352458506070947 !CS1 manut: Nomes múltiplos: lista de autores (link)
Bennett M, Heard R (2004). Bennett, Michael H, ed. «Hyperbaric oxygen therapy for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD003057. PMID14974004. doi:10.1002/14651858.CD003057.pub2
Pugliatti, M; Sotgiu, S, Rosati, G (Jul. 2002). «The worldwide prevalence of multiple sclerosis». Clinical neurology and neurosurgery. 104 (3): 182–91. PMID12127652. doi:10.1016/S0303-8467(02)00036-7 !CS1 manut: Nomes múltiplos: lista de autores (link)
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). «Vitamin D: an evidence-based review». J Am Board Fam Med. 22 (6): 698–706. PMID19897699. doi:10.3122/jabfm.2009.06.090037 !CS1 manut: Nomes múltiplos: lista de autores (link)
Kappos L; Radue, EW; O'Connor, P; Polman, C; Hohlfeld, R; Calabresi, P; Selmaj, K; Agoropoulou, C; Leyk, M (fevereiro de 2010). «A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis». N Eng J Med. 362 (5): 387–401. PMID20089952. doi:10.1056/NEJMoa0909494
Cohen JA; Barkhof, F; Comi, G; Hartung, HP; Khatri, BO; Montalban, X; Pelletier, J; Capra, R; Gallo, P (fevereiro de 2010). «Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis». N Eng J Med. 362 (5): 402–415. PMID20089954. doi:10.1056/NEJMoa0907839
Patel PN (setembro de 2007). «Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed». Ann Pharmacother. 41 (9): 1549–50. PMID17623758. doi:10.1345/aph.1H083
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G (2008). «A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis». Multiple Sclerosis. 14 (8): 1076–83. PMID18728058. doi:10.1177/1352458508095828 !CS1 manut: Nomes múltiplos: lista de autores (link)
Harris VK, Sadiq SA (2009). «Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making». Mol Diagn Ther. 13 (4): 225–44. PMID19712003. doi:10.2165/11313470-000000000-00000
Ghezzi A, Comi G, Federico A (fevereiro de 2011). «Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis». Neurol. Sci. 32 (1): 17–21. PMID21161309. doi:10.1007/s10072-010-0458-3 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dorne H, Zaidat OO, Fiorella D, Hirsch J, Prestigiacomo C, Albuquerque F, Tarr RW. (outubro de 2010). «Chronic cerebrospinal venous insufficiency and the doubtful promise of an endovascular treatment for multiple sclerosis». J NeuroIntervent Surg. 2 (4): 309–311. doi:10.1136/jnis.2010.003947 !CS1 manut: Nomes múltiplos: lista de autores (link)
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R (12 de fevereiro de 2010). «Chronic cerebrospinal venous insufficiency and multiple sclerosis». Annals of Neurology. Annals of neurology. 67 (3): 286–90. PMID20373339. doi:10.1002/ana.22001 !CS1 manut: Nomes múltiplos: lista de autores (link)
Clanet M (junho de 2008). «Jean-Martin Charcot. 1825 to 1893»(PDF). Int MS J. 15 (2): 59–61. PMID18782501 * Charcot, J. (1868). «Histologie de la sclerose en plaques». Gazette des hopitaux, Paris. 41: 554–5
Milo R, Kahana E (março de 2010). «Multiple sclerosis: geoepidemiology, genetics and the environment». Autoimmunity Reviews. 9 (5): A387-94. PMID19932200. doi:10.1016/j.autrev.2009.11.010
Nakahara J, Maeda M, Aiso S, Suzuki N (fevereiro de 2012). «Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy». Clinical Reviews in Allergy & Immunology. 42 (1): 26–34. PMID22189514. doi:10.1007/s12016-011-8287-6
Tsang BK, Macdonell R (dezembro de 2011). «Multiple sclerosis- diagnosis, management and prognosis». Australian Family Physician. 40 (12): 948–55. PMID22146321
Rosati G (abril de 2001). «The prevalence of multiple sclerosis in the world: an updata». Neurol. Sci. 22 (2): 117–39. PMID11603614. doi:10.1007/s100720170011
Clanet M (junho de 2008). «Jean-Martin Charcot. 1825 to 1893»(PDF). Int MS J. 15 (2): 59–61. PMID18782501 * Charcot, J. (1868). «Histologie de la sclerose en plaques». Gazette des hopitaux, Paris. 41: 554–5
Ascherio A, Munger KL (abril de 2007). «Environmental risk factors for multiple sclerosis. Part I: the role of infection». Ann. Neurol. 61 (4): 288–99. PMID17444504. doi:10.1002/ana.21117
Fred D. Lublin; Reingold SC (abril de 1996). «Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis». Neurology. 46 (4): 907–11. PMID8780061
Petzold A, Fraser CL, Abegg M; et al. (2022). «Diagnosis and classification of optic neuritis». The Lancet Neurology. 21 (12): 1120–1134. PMID36179757. doi:10.1016/S1474-4422(22)00200-9 !CS1 manut: Uso explícito de et al. (link) !CS1 manut: Nomes múltiplos: lista de autores (link)
Tataru N, Vidal C, Decavel P, Berger E, Rumbach L (2006). «Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis». Neuroepidemiology. 27 (1): 28–32. PMID16804331. doi:10.1159/000094233 !CS1 manut: Nomes múltiplos: lista de autores (link)
Heesen C, Mohr DC, Huitinga I; et al. (março de 2007). «Stress regulation in multiple sclerosis: current numeros and concepts». Mult. Scler. 13 (2): 143–8. PMID17439878. doi:10.1177/1352458506070772 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dyment DA, Ebers GC, Sadovnick AD (fevereiro de 2004). «Genetics of multiple sclerosis». Lancet Neurol. 3 (92): 104–10. PMID14747002. doi:10.1016/S1474-4422(03)00663-X !CS1 manut: Nomes múltiplos: lista de autores (link)
Ascherio A, Munger KL (junho de 2007). «Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors». Ann. Neurol. 61 (6): 504–13. PMID17492755. doi:10.1002/ana.21141
Ascherio A, Munger KL, Simon KC (junho de 2010). «Vitamin D and multiple sclerosis». Lancet Neurol. 9 (6): 599–612. PMID20494325. doi:10.1016/S1474-4422(10)70086-7 !CS1 manut: Nomes múltiplos: lista de autores (link)
Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R (1998). «Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada». Int J Epidemiol. 27 (5): 845–52. PMID9839742. doi:10.1093/ije/27.5.845 !CS1 manut: Nomes múltiplos: lista de autores (link)
Pittock SJ, Lucchinetti CF (março de 2007). «The pathology of MS: new insights and potential clinical applications». Neurologist. 13 (2): 45–56. PMID17351524. doi:10.1097/01.nrl.0000253065.31662.37
Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C (novembro de 2001). «T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis». Glia. 36 (2): 220–34. PMID11596130. doi:10.1002/glia.1111 !CS1 manut: Nomes múltiplos: lista de autores (link)
Poser CM, Brinar VV (junho de 2004). «Diagnostic criteria for multiple sclerosis: an historical review». Clin Neurol Neurosurg. 106 (3): 147–58. PMID15177763. doi:10.1016/j.clineuro.2004.02.004
McDonald WI, Compston A, Edan G; et al. (julho de 2001). «Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis». Ann. Neurol. 50 (1): 121–7. PMID11456302. doi:10.1002/ana.1032 !CS1 manut: Nomes múltiplos: lista de autores (link)
Polman CH, Reingold SC, Edan G; et al. (dezembro de 2005). «Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"». Ann. Neurol. 58 (6): 840–6. PMID16283615. doi:10.1002/ana.20703 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rashid W, Miller DH (fevereiro de 2008). «Recent advances in neuroimaging of multiple sclerosis». Semin Neurol. 28 (1): 46–55. PMID18256986. doi:10.1055/s-2007-1019127
Link H, Huang YM (novembro de 2006). «Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an updata on methodology and clinical usefulness». J. Neuroimmunol. 180 (1–2): 17–28. PMID16945427. doi:10.1016/j.jneuroim.2006.07.006
Pittock SJ, Rodriguez M (2008). «Benign multiple sclerosis: a distinct clinical entity with therapeutic implications». Curr. Top. Microbiol. Immunol. Current Topics in Microbiology and Immunology. 318: 1–17. ISBN978-3-540-73676-9. PMID18219812. doi:10.1007/978-3-540-73677-6_1
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (maio de 2005). «Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis». Lancet Neurol. 4 (5): 281–8. PMID15847841. doi:10.1016/S1474-4422(05)70071-5 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M (abril de 2006). «Secondary progressive multiple sclerosis: current knowledge and future challenges». Lancet Neurol. 5 (4): 343–54. PMID16545751. doi:10.1016/S1474-4422(06)70410-0 !CS1 manut: Nomes múltiplos: lista de autores (link)
Stadelmann C, Brück W (novembro de 2004). «Lessons from the neuropathology of atypical forms of multiple sclerosis». Neurol. Sci. 25 (Suppl 4): S319–22. PMID15727225. doi:10.1007/s10072-004-0333-1
Burton JM, O'Connor PW, Hohol M, Beyene J (2009). Burton, Jodie M, ed. «Oral versus intravenous steroids for treatment of relapses in multiple sclerosis». Cochrane Database Syst Rev (3): CD006921. PMID19588409. doi:10.1002/14651858.CD006921.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Comi G (outubro de 2009). «Treatment of multiple sclerosis: role of natalizumab». Neurol. Sci. 30. Suppl 2 (S2): S155–8. PMID19882365. doi:10.1007/s10072-009-0147-2
Johnson KP (2007). «Control of multiple sclerosis relapses with immunomodulating agents». J. Neurol. Sci. 256 (Suppl 1): S23–8. PMID17350652. doi:10.1016/j.jns.2007.01.060
Martinelli Boneschi F, Rovaris M, Capra R, Comi G (2005). Martinelli Boneschi, Filippo, ed. «Mitoxantrone for multiple sclerosis». Cochrane database of systematic reviews (Online) (4): CD002127. PMID16235298. doi:10.1002/14651858.CD002127.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Sládková T, Kostolanský F (2006). «The role of cytokines in the immune response to influenza A virus infection». Acta Virol. 50 (3): 151–62. PMID17131933
Munari L, Lovati R, Boiko A (2004). Munari, Luca M., ed. «Therapy with glatiramer acetate for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD004678. PMID14974077. doi:10.1002/14651858.CD004678 !CS1 manut: Nomes múltiplos: lista de autores (link)
Tremlett H, Oger J (novembro de 2004). «Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis». J. Neurol. 251 (11): 1297–303. PMID15592724. doi:10.1007/s00415-004-0619-5
Khan F, Turner-Stokes L, Ng L, Kilpatrick T (2007). Khan, Fary, ed. «Multidisciplinary rehabilitation for adults with multiple sclerosis». Cochrane Database Syst Rev (2): CD006036. PMID17443610. doi:10.1002/14651858.CD006036.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Smith, Cath; Leigh Hale; Kärin Olson; Anthony Schneiders (2009). «How does exercise influence fatigue in people with multiple sclerosis?». Disability and Rehabilitation. 31 (9): 685–692. PMID18841515. doi:10.1080/09638280802273473 !CS1 manut: Nomes múltiplos: lista de autores (link)
Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G (2005). Kwakkel, Gert, ed. «Exercise therapy for multiple sclerosis». Cochrane Database of Systematic Reviews. CD003980 (1): CD003980. PMID15674920. doi:10.1002/14651858.CD003980.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Dalgas U, Stenager E, Jakobsen J; et al. (2009). «Resistance training improves muscle strength and functional capacity in multiple sclerosis». Neurology. 73 (18): 1478–1484. PMID19884575. doi:10.1212/WNL.0b013e3181bf98b4 !CS1 manut: Nomes múltiplos: lista de autores (link)
Olsen SA (2009). «A review of complementary and alternative medicine (CAM) by people with multiple sclerosis». Occup Ther Int. 16 (1): 57–70. PMID19222053. doi:10.1002/oti.266
Farinotti M, Simi S, Di Pietrantonj C; et al. (2007). Farinotti, Mariangela, ed. «Dietary interventions for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD004192. PMID17253500. doi:10.1002/14651858.CD004192.pub2 !CS1 manut: Nomes múltiplos: lista de autores (link)
Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E (2006). «Cannabis use in patients with multiple sclerosis». Mult. Scler. 12 (5): 646–51. PMID17086912. doi:10.1177/1352458506070947 !CS1 manut: Nomes múltiplos: lista de autores (link)
Bennett M, Heard R (2004). Bennett, Michael H, ed. «Hyperbaric oxygen therapy for multiple sclerosis». Cochrane database of systematic reviews (Online) (1): CD003057. PMID14974004. doi:10.1002/14651858.CD003057.pub2
Pugliatti, M; Sotgiu, S, Rosati, G (Jul. 2002). «The worldwide prevalence of multiple sclerosis». Clinical neurology and neurosurgery. 104 (3): 182–91. PMID12127652. doi:10.1016/S0303-8467(02)00036-7 !CS1 manut: Nomes múltiplos: lista de autores (link)
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). «Vitamin D: an evidence-based review». J Am Board Fam Med. 22 (6): 698–706. PMID19897699. doi:10.3122/jabfm.2009.06.090037 !CS1 manut: Nomes múltiplos: lista de autores (link)
Kappos L; Radue, EW; O'Connor, P; Polman, C; Hohlfeld, R; Calabresi, P; Selmaj, K; Agoropoulou, C; Leyk, M (fevereiro de 2010). «A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis». N Eng J Med. 362 (5): 387–401. PMID20089952. doi:10.1056/NEJMoa0909494
Cohen JA; Barkhof, F; Comi, G; Hartung, HP; Khatri, BO; Montalban, X; Pelletier, J; Capra, R; Gallo, P (fevereiro de 2010). «Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis». N Eng J Med. 362 (5): 402–415. PMID20089954. doi:10.1056/NEJMoa0907839
Patel PN (setembro de 2007). «Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed». Ann Pharmacother. 41 (9): 1549–50. PMID17623758. doi:10.1345/aph.1H083
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G (2008). «A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis». Multiple Sclerosis. 14 (8): 1076–83. PMID18728058. doi:10.1177/1352458508095828 !CS1 manut: Nomes múltiplos: lista de autores (link)
Harris VK, Sadiq SA (2009). «Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making». Mol Diagn Ther. 13 (4): 225–44. PMID19712003. doi:10.2165/11313470-000000000-00000
Ghezzi A, Comi G, Federico A (fevereiro de 2011). «Chronic cerebro-spinal venous insufficiency (CCSVI) and multiple sclerosis». Neurol. Sci. 32 (1): 17–21. PMID21161309. doi:10.1007/s10072-010-0458-3 !CS1 manut: Nomes múltiplos: lista de autores (link)
Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R (12 de fevereiro de 2010). «Chronic cerebrospinal venous insufficiency and multiple sclerosis». Annals of Neurology. Annals of neurology. 67 (3): 286–90. PMID20373339. doi:10.1002/ana.22001 !CS1 manut: Nomes múltiplos: lista de autores (link)
ninds.nih.gov
«NINDS Multiple Sclerosis Information Page». National Institute of Neurological Disorders and Stroke. 19 de novembro de 2015. Consultado em 6 de março de 2016. Arquivado do original em 13 de fevereiro de 2016
«NINDS Multiple Sclerosis Information Page». National Institute of Neurological Disorders and Stroke. 19 de novembro de 2015. Consultado em 6 de março de 2016. Arquivado do original em 13 de fevereiro de 2016